Package Leaflet: Information for the User
Telzir 700mg film-coated tablets
fosamprenavir
Read all of this leaflet carefully before you start takingthismedicine, because it contains important information for you.
Contents of the pack
Telzir is used to treat HIV (Human Immunodeficiency Virus) infection.
Telzir is a type of medicine known as an antiretroviral. Telzir is taken with low doses of another medicine, ritonavir, which increases the levels of Telzir in the blood. Telzir belongs to a group of antiretroviral medicines called protease inhibitors. Protease is an enzyme produced by HIV that allows the virus to multiply in blood cells (CD4 cells). By blocking the action of protease, Telzir stops the multiplication of HIV and the infection of more CD4 cells.
Telzir administered with low doses of ritonavir is used in combination with other antiretroviral medicines (“combination therapy”) in the treatment of adults, adolescents, and children over 6 years infected with HIV.
HIV can become resistant to anti-HIV medicines. To avoid this happening and to slow down the progression of your disease, it is very important that you continue to take all your medicines as prescribed by your doctor.
Telzir does not prevent the transmission of HIV. HIV infection is transmitted through sexual contact with infected people or through the transfer of infected blood (e.g., by sharing needles).
Telzir is taken in combination with low doses of ritonavir and other antiretroviral agents.Therefore, it is important that you carefully read the package leaflet provided with this medicine. If you have any further questions about ritonavir or the other prescribed medicines, please consult your doctor or pharmacist.
Do not take Telzir
Tell your doctor if you are in any of these situations.
Be careful with Telzir
Consult your doctor or pharmacist before starting to take Telzir:
Some patients may also develop diabetes during treatment with these medicines.
Tell your doctor if you are in any of these situations.While taking this medicine, you will require extra check-ups, including blood tests.
Your doctor will monitor your blood glucose levels before and during treatment with Telzir.
Be alert to important symptoms
Some patients taking HIV medicines develop other symptoms, which can be serious.
These may be:
It is essential that you know the signs and symptoms that may appear while taking Telzir.
Please read the information on “Other side effects of combination HIV therapy” in section 4 of this leaflet.If you have any questions about this information or the recommendations given:
Consult your doctor.
You may experience skin rashes
However, if you develop a skin rash, you can continue taking Telzir. You may be treated with antihistamines. Rarely, the skin rash can be severe and serious (Stevens-Johnson syndrome). If this happens, you must stop taking Telzir immediately and never take it again.
Other medicines and Telzir
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicine, including herbal medicines or those bought without a prescription. Your doctor will decide if these medicines are suitable for you to take with Telzir and ritonavir. This is veryimportant, as taking certain types of medicines at the same time as Telzir and ritonavir can enhance or weaken the effect of other medicines. This can, in some cases, lead to serious situations.
There are some medicines that must not be taken with Telzir.You must review the list of medicines in the section “Do not take Telzir” at the beginning of section 2 of this leaflet.
The following medicines are not recommended to be taken with Telzir/ritonavir:
You will require close monitoring if you are taking the following medicines with Telzir/ritonavir:
You may need to change your dose of Telzir if you are taking
Hormonal contraception
Taking Telzir and ritonavir while taking the contraceptive pill may damage your liver and may make the contraceptive less effective.
Use a non-hormonal contraceptive method, such as a condom.
No studies have been conducted on the use of Telzir/ritonavir with other hormonal therapies, such as hormone replacement therapy (HRT).
Pregnancy
If you are pregnant, think you may be pregnant, or plan to become pregnant:
Consult your doctor or pharmacistbefore using this medicine.
Breastfeeding
It is not recommendedthat HIV-infected women breastfeed their babies, as HIV infection can be transmitted to the baby through breast milk. It is not known if the components of Telzir can pass into breast milk. If you are breastfeeding or plan to breastfeed, consult your doctor as soon as possible.
Driving and using machines
Telzir may make you feel dizzy and cause other effects that reduce your attention.
Do not drive or operate machinery or toolsunless you feel well.
Keep regular contact with your doctor
Telzir helps control your disease, but it does not cure HIV infection. You must continue to take it every day to avoid your disease worsening. You may still develop other infections and diseases associated with HIV infection.
Keep in touch with your doctor and do not stop taking Telzirwithout your doctor's advice.
Telzir contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per dose; this is essentially “sodium-free”.
Follow exactly the instructions for administration ofthis medicinegiven by your doctor.It is very important that you take the complete daily dose of Telzir and ritonavir as prescribed by your doctor. Do not take morethan the recommended dose. If in doubt, consult your doctor or pharmacist again.
Swallow the tablets whole with water or another drink. Telzir tablets can be taken with or without food. Telzir is also available in liquid form (oral suspension) for patients who are unable to swallow tablets. (Read the package leaflet of Telzir oral suspension for recommendations on how to take it with or without food).
Adults
The recommended dose is one 700 mg Telzir tablet twice a daywith 100 mg of ritonavir twice a day.
Children over 6 years and weighing at least39 kg
Children in this group can take the adult dose of one 700 mg Telzir tablet twice a daywith 100 mg of ritonavir twice a day, provided they can swallow the tablets whole.
Children over 6 years and weighing less than39 kg
Use the oral suspension of Telzir.
Adults with liver disease
If you have mild liver disease, the dose is one 700 mg Telzir tablet twice a daywith 100 mg of ritonavir only once a day. If you have moderate or severe liver disease, the dose of Telzir must be reduced. This dose adjustment cannot be made with Telzir tablets, so you must use the oral suspension of Telzir.
If you take more Telzir than you should
If you take more Telzir than the dose prescribed by your doctor:
Consult your doctor or pharmacist immediately.
If you forget to take Telzir
If you forget to take a dose of Telzir, take it as soon as you remember and then continue your treatment as before. Do not take a double dose to make up for forgotten doses.
Do not stop treatment with Telzir without your doctor's advice
Take Telzir for as long as your doctor recommends. Do not stop treatment unless your doctor advises you to do so.
During HIV treatment, there may be an increase in weight and levels of glucose and lipids in the blood. This may be partly related to the recovery of health and lifestyle, and in the case of blood lipids, sometimes to HIV medications themselves. Your doctor will monitor these changes.
Like all medications, this medication may produce adverse effects, although not all people will experience them. When treating an HIV infection, it is not always possible to determine if some of the adverse effects that appear are caused by Telzir, by other medications taken at the same time, or by the HIV infection. For this reason, it is very important that you inform your doctor about any change that occurs in your health.
Very Common Adverse Effects
May affect more than 1 in 10 people treated:
Common Adverse Effects
May affect up to 1 in 10 people treated:
Uncommon Adverse Effects
May affect up to 1 in 100 people treated:
Rare Adverse Effects
May affect up to 1 in 1,000 people treated:
You may experience muscle problems
There have been reports of muscle pain, increased sensitivity, or weakness in the muscles, particularly with antiretroviral treatments that include protease inhibitors and nucleoside analogs. In rare cases, these muscle disorders have been severe (rhabdomyolysis). If you notice muscle problems:
?Tell your doctor.
Patients with hemophilia may bleed more
In patients with hemophilia A and B, increased bleeding has been observed while being treated with protease inhibitors. If this happens to you:
?Consult your doctor immediately.
If you experience adverse effects
?Consult your doctor or pharmacist, even if it's an adverse effect that is not listed in this leaflet.
Other Adverse Effects of HIV Treatment
Reappearance of previous infections
Patients with advanced HIV infection (AIDS) have a weakened immune system and are more prone to developing severe infections (opportunistic infections). When these patients start treatment, it may happen that previous infections recur, causing signs and symptoms of inflammation. These symptoms are likely caused by the immune system becoming more potent and starting to fight these infections.
In addition to opportunistic infections, autoimmune disorders (a condition that occurs when the immune system attacks healthy body tissue) may also appear after you start taking medications for your HIV treatment. Autoimmune disorders can appear many months after starting treatment. If you notice any symptoms of infection or other symptoms such as muscle weakness, weakness starting in the hands and feet and moving up to the torso, palpitations, tremors, or hyperactivity, tell your doctor immediately to receive the necessary treatment.
If you have any symptoms of infection or signs of inflammation while taking Telzir:
?Tell your doctor immediately. Do not take other medications for the infectionwithout consulting your doctor.
You may experience bone problems
Some patients on combined antiretroviral therapy for HIV develop osteonecrosis. In this condition, parts of the bone tissue die due to reduced blood supply to the bones.
Patients may be more likely to experience this condition:
Be especially careful if you notice:
If you detect any of these symptoms:
?Tell your doctor.
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it's a possible adverse effect that is not listed in this leaflet. You can also report them directly through the national reporting system included in Appendix V. By reporting adverse effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of sight and reach of children.
Do not use this medication after the expiration date on the box and bottle.
Telzir does not require special storage conditions.
Medications should not be disposed of through wastewater or household waste. Ask your pharmacist how to dispose of the packaging and any unused medication. This will help protect the environment.
Telzir Composition
Product Appearance and Package Contents
Telzir is supplied in plastic bottles containing 60 film-coated tablets. The tablets are capsule-shaped, biconvex, pink, and marked with "GXLL7" on one side.
Telzir is also available as an oral suspension for patients who cannot swallow tablets.
Marketing Authorization Holder and Manufacturer
Manufacturer | Marketing Authorization Holder |
Glaxo Wellcome S.A. Avenida de Extremadura, 3 09400 Aranda de Duero (Burgos) Spain | ViiV Healthcare BV Van Asch van Wijckstraat 55H 3811 LP Amersfoort Netherlands |
You can request more information about this medication by contacting the local representative of the marketing authorization holder:
België/Belgique/Belgien ViiV Healthcare srl/bv Tél/Tel: + 32 (0) 10 85 65 00 | Lietuva ViiV Healthcare BV Tel: +370 80000334 |
???????? ViiV Healthcare BV Te?.: +359 80018205 | Luxembourg/Luxemburg ViiV Healthcare srl/bv Belgique/Belgien Tél/Tel: + 32 (0) 10 85 65 00 |
Ceská republika GlaxoSmithKline s.r.o. Tel: + 420 222 001 111 cz.info @gsk.com | Magyarország ViiV Healthcare BV Tel.: +36 80088309 |
Danmark GlaxoSmithKline Pharma A/S Tlf: + 45 36 35 91 00 dk-info@gsk.com | Malta ViiV Healthcare BV Tel: +356 80065004 |
Deutschland ViiV Healthcare GmbH Tel.: + 49 (0)89 203 0038-10 viiv.med.info@viivhealthcare.com | Nederland ViiV Healthcare BV Tel: + 31 (0) 33 2081199 |
Eesti ViiV Healthcare BV Tel: +372 8002640 | Norge GlaxoSmithKline AS Tlf: + 47 22 70 20 00 |
Ελλ?δα GlaxoSmithKline Μονοπρ?σωπη A.E.B.E. Τηλ: + 30 210 68 82 100 | Österreich GlaxoSmithKline Pharma GmbH Tel: + 43 (0)1 97075 0 at.info@gsk.com |
España Laboratorios ViiV Healthcare, S.L. Tel: + 34 900 923 501 es-ci@viivhealthcare.com | Polska GSK Services Sp. z o.o. Tel.: + 48 (0)22 576 9000 |
France ViiV Healthcare SAS Tél: + 33 (0)1 39 17 6969 Infomed@viivhealthcare.com | Portugal VIIVHIV HEALTHCARE, UNIPESSOAL, LDA. Tel: + 351 21 094 08 01 viiv.fi.pt@viivhealthcare.com |
Hrvatska ViiV Healthcare BV Tel: +385 800787089 | România ViiV Healthcare BV Tel: +40 800672524 |
Ireland GlaxoSmithKline (Ireland) Limited Tel: + 353 (0)1 4955000 | Slovenija ViiV Healthcare BV Tel: +386 80688869 |
Ísland Vistor hf. Sími: +354 535 7000 | Slovenská republika ViiV Healthcare BV Tel: +421 800500589 |
Italia ViiV Healthcare S.r.l. Tel: + 39 (0)45 7741600 | Suomi/Finland GlaxoSmithKline Oy Puh/Tel: + 358 (0)10 30 30 30 Finland.tuoteinfo@gsk.com |
Κ?προς ViiV Healthcare BV Τηλ: +357 80070017 | Sverige GlaxoSmithKline AB Tel: + 46 (0)8 638 93 00 info.produkt@gsk.com |
Latvija ViiV Healthcare BV Tel: +371 80205045 | United Kingdom (Northern Ireland) ViiV Healthcare BV Tel: + 44 (0)800 221441 customercontactuk@gsk.com |
Date of the Last Revision of this Leaflet:
Detailed information about this medication is available on the European Medicines Agency website: http://www.ema.europa.eu.